Mayo Clinic
VC Fund
Rochester, United States
Mayo Clinic is a VC fund in Rochester focused on Health Care and Biotechnology. Mayo Clinic, a not-for-profit medical group practice, provides medical care, research, and education services. It offers medical care services in various specialties, including diabetes and endocrinology, gastroenterology, gynecology, cancer, neurology and neurosurgery, orthopedics, pulmonology, rheumatology, nephrology, urology, and cardiology andheart surgery.
- Total investments:
- 116
- Last investment:
- Lead investor:
- 14%
Last updated:
For AI agents: llms.txt
Industries Mayo Clinic invests in
Stages Mayo Clinic invests in
Countries Mayo Clinic invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $100k–$6M
- Series A
- $3.5M–$40M
- Series B
- $8M–$100M
Investment Focus
Industry
- Health Care 48 (41%)
- Biotechnology 23 (20%)
- Medical 22 (19%)
- Medical Device 17 (15%)
- Artificial Intelligence 14 (12%)
Stage
- Series A 22 (19%)
- Seed 18 (16%)
- Series B 18 (16%)
- Funding Round 10 (9%)
- Series C 6 (5%)
Country
- United States 61 (53%)
- Canada 2 (2%)
- Israel 2 (2%)
- China 1 (1%)
- India 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Andrew Coyne
Chief Information Security Officer
|
Chief Information Security Officer | Total investments: 0 | Find email | |
Clark Otley
Professor and Consultant, Department of Dermatology
|
Professor and Consultant, Department of Dermatology | Total investments: 1 | Find email | |
Eric Funk
Chief Resident
|
Chief Resident | Total investments: 0 | Find email | |
Gianrico Farrugia
Physician
|
Physician | Total investments: 2 | Find email | |
Jonathan J. Oviatt
CLO and Secretary
|
CLO and Secretary | Total investments: 0 | Find email | |
| See all 14 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Transcripta Bio
|
Transcripta Bio is a company dedicated to drug discovery, with a focus on numerous diseases at once, at a never-before-seen pace and scale, with lesser risk and greater assurance. | $24M / Series A / Jul 22, 2026 | |
ElectroKare
|
Electrokare is a continuous, non-invasive blood biomarker platform that turns ECG signals into real-time physiological insights. Our AI models translate existing wearable and clinical ECG data into estimates of key biomarkers like potassium and sodium, enabling earlier intervention, better decision-making, and proactive care.We’re building theintelligence layer that makes the human body continuously measurable. | Seed / Jul 01, 2026 | |
SyntaxBio
|
SyntaxBio develops CRISPR/Cas9-based, genetic programming platform that converts cells into biological computers using DNA-based instructions that read like lines of code. SyntaxBio's platform can program cells without the need for consistent external intervention. | $14.4M / Series A / Jun 21, 2026 | |
Techcyte
|
Techcyte is a cloud-based, SaaS provider and world leader in AI-based cellular digital diagnostics. that uses deep learning image analysis to help labs and clinics become more efficient and accurate. The platform is HIPAA compliant, CE marked and supports tests across hematology, cytology, bacteriology and parasitology. Techcyte's hassolutions for human, veterinary and environmental clinics and labs. Techcyte’s Clinical Pathology AI Platform uses deep machine learning to perform automated analysis of whole slide microscopy images, revolutionizing digital diagnostics for human, animal, and environmental clinics and labs. | $15M / Venture - Series Unknown / Apr 30, 2026 | |
ViewsML
|
ViewsML leverages artificial intelligence to enhance virtual diagnostics and precision medicine. The company focuses on transforming spatial biology and translational research by utilizing virtual biomarkers. Their technology aims to improve patient outcomes by providing deeper insights into healthcare diagnostics. ViewsML is involved in developingimmunohistochemistry technology to streamline the diagnostic process and support research objectives efficiently. | $4.9M / Seed / Apr 20, 2026 | |
Sana Biotechnology
|
Sana Biotechnology focuses on creating and delivering engineered cells as medicine for patients.Recent scientific advances make it possible to reprogram cells in the body or replace damaged cells and tissues, creating a new class of medicines to treat a broad array of diseases.The company is a team of scientists, clinicians and biotechnologyveterans focused on creating an enduring company that makes meaningful medicines and will change the approach in treating diseases. | $25M / Post-IPO Equity / Apr 13, 2026 | |
WHOOP
|
WHOOP is the performance optimization system that tracks recovery, training, and sleeping hours thus helping elite athletes and teams win.The company provides athletes, coaches, and trainers with a continuous understanding of strain and recovery to balance training, reduce injuries, and predict performance. It creates a product that makesindividuals and teams perform at a higher level through a deeper understanding of their bodies and daily lives. The WHOOP Strap 3.0 collects physiological data 24/7 to provide an accurate and granular understanding of the body. Aurelian Nicolae, John Capodilupo, and Will Ahmed established WHOOP in 2012 and in Boston, Massachusetts. | $575M / Series G / Mar 31, 2026 | |
Sub-Q Bionics
|
Sub-Q Bionics is a medtech company, that aids the management of chronic pain and debilitating symptoms of lymphedema specially for women. | $1.5M / Pre-Seed / Mar 31, 2026 | |
Vitestro
|
Vitestro transform patient care with autonomous blood drawing technology. | $70M / Series B / Mar 10, 2026 | |
OpenEvidence
|
OpenEvidence provides an artificial intelligence medical information platform that organizes and synthesizes peer-reviewed clinical research to help physicians access evidence-based insights for clinical decision support. Its products include an AI-powered medical search engine that quickly retrieves and cites relevant literature from majorjournals and tools like DeepConsult that generate comprehensive research syntheses for complex clinical questions. The platform also integrates features that support clinical documentation and evidence retrieval during patient encounters, aiming to streamline how healthcare professionals find and apply clinical evidence. OpenEvidence delivers responses grounded in sourced medical research and supports workflows that assist clinicians in evaluating and interpreting medical knowledge. | $250M / Series D / Jan 21, 2026 | |
| See all 116 investments → | |||
Co-Investors
Aberdare Ventures
6 deals together
Cardinal Health
6 deals together
Kaiser Permanente
6 deals together
Sequoia Capital
6 deals together
Bay City Capital
5 deals together
Canaan Partners
5 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Mayo Clinic invest in?
Mayo Clinic invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Seed stage. Most of the 116 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Mayo Clinic's check size?
Mayo Clinic typically joins rounds of $100k–$6M at Seed, $3.5M–$40M at Series A and $8M–$100M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Mayo Clinic participates in.
How do I contact Mayo Clinic?
Public channels for Mayo Clinic include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Mayo Clinic?
The team at Mayo Clinic includes Andrew Coyne (Chief Information Security Officer), Clark Otley (Professor and Consultant, Department of Dermatology) and Eric Funk (Chief Resident), among 14 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
